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At the mRNA level, sodium channel isoforms, including SCN1A, 2A 3A, 4A, 5A, 8A, 9A, 10A and SCN1B, 2B, 3B, 4B, were detected in the human SAN using real tie PCR (n=20). Immunostaining data showed a 
relative density for cardiac Nav1.5 in right atria (0.12 ± 0.03) compared to SAN (0.07 ± 0.02 (n=6, p<0.05)).  It also shows a higher relative density for neuronal Nav1.6 in SAN (0.36 ± 0.07) compared to right 
atria ± 0.05 (n=6, p<0.05)).  Western blot data also confirms for Nav1.5 in the right atria (8.97 ± 3.78) compared to the SAN (2.33 ± 1.40 (n=6, p<0.05)).
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Proteasomes are protein complexes which can be 
targeted for protein degradation via proteolysis. Molecules 
known as proteolysis-targeting chimeras, or PROTACs, 
can be designed to target a specific protein of interest, as 
well as an E3 ligase protein which causes the target 




Most linkers are designed using simple alkyl or 
polyethyleneglycol chains. An analysis of the drug 
properties of andarine-based PROTACS shows that 
the alkyl linkers between 2 and 7 atoms in length have 
ClogP values in the 4-6 range, which according Maple 
et al. is expected to give good activity due to 
permeability. The shortest chain (n = 1) gives a ClogP
of 3.23, but more importantly may not be long enough 
to allow formation of the ternary complex, the PROTAC 
molecule forming a bridge between the two proteins 
(AR and E3 ligase). The longest chains examined (n = 
9 and n = 11) have ClogP values that are above 6, 
suggesting that they may be too lipophilic. The PEG 
linked analogues tell a completely different story. In this 
case, ClogP decreases as a function of chain length, 
suggesting that lengthening of the chain may be 
counterproductive from the perspective of potency. In 
addition, longer chain lengths of the PEG series are 
associated with increased pol r surface areas, while 
the tPSA values for the alkyl chains remain constant.
BACKGROUND
Hepatocellular carcinoma is one of the most common 
types of liver cancer and is the third leading cause of 
cancer death worldwide.  Androgen receptors have 
been studied as potential targets for the treatment of 
hepatocellular carcinoma. Androgen receptors ligands 
can be incorporated into PROTACs to be used in the 
targeted degradation of the androgen receptor. 
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FUTURE DIRECTIONS
PROTACs could be a potential treatment for not only 
hepatocellular carcinoma, but also other types of cancers 
as well.  Based on the research of AR ligands and 
PROTACS, synthesis of the most promising molecules will 
be synthesized and studied in the future.
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The Protein Data Bank was used to study the x-ray crystal 
structures of androgen receptor modulators to determine 
binding mode and identify a suitable point of attachment 
for the linker. As an example, andarine is shown below. In 
this crystal structure, the amide group on the right side of 
andarine is shown to be projecting out of the binding 
pocket. Therefore, linker attachment should be at this site.
A database consisting of 1662 PROTACs and 202 
warheads was used to collect the data in the results.
Max (AR) Min (AR) Max (AR PROTAC) Min (AR PROTAC)
Molecular Weight 477.443 311.388 1154.355 829.398
logP 5.19 2.7 7.22 4.97
Hydrogen Bond 
Acceptor Count 6 3 14 9
Hydrogen Bond 
Donor Count 2 0 5 2
Rotatable Bonds 6 3 24 7
Topological Surface 
Area 107.26 41.61 228.88 152.15

















Linker Warhead E3 ligase
4-hydroxythalidomide, X = OH
pomalidomide, X = NH2
Based on work previously done in the Fuchs lab for the 
design of protein degraders against leukemia, thalidomide 
analogues were selected as the E3 ligase. This decision is 
based on the relative ease of thalidomide synthesis as 
compared to VHL ligands. The linker would be selected 
from alkyl and polyethylene glycol units as suggested by 
Maple et al. Andarine was selected as the warhead to 
target the androgen receptor. The relative connectivity of 
these pieces remained to be determined, particularly the 



































































































































































# Atoms in 
linker
MW ClogP tPSA
1 1 713.58 3.23 232.25
2 3 741.63 4.03 232.25
3 5 769.69 4.67 232.25
4 7 797.74 5.73 232.25
5 9 825.80 6.79 232.25
6 11 853.85 7.85 232.25
7 5 (1 - O) 771.66 3.70 241.48
8 8 (2 – O) 815.71 3.53 250.71









































Drug Properties of AR Ligands
logP Rotatable bonds H bond acceptors
































Drug Properties of AR Warhead PROTACS
logP Hydrogen Bond Acceptor Count Hydrogen Bond Donor Count
Rotatable Bond Count Topological Polar Surface Area Molecular Weight
